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Background: Extending the duration of adjuvant endocrine therapy reduces the risk of recurrence in a subset of women with
early-stage hormone receptor-positive (HRþ) breast cancer. Validated predictive biomarkers of endocrine response could
significantly improve patient selection for extended therapy. Breast cancer index (BCI) [HOXB13/IL17BR ratio (H/I)] was evaluated
for its ability to predict benefit from extended endocrine therapy in patients previously randomized in the Adjuvant
Tamoxifen—To Offer More? (aTTom) trial.
Patients and methods: Trans-aTTom is a multi-institutional, prospective–retrospective study in patients with available
formalin-fixed paraffin-embedded primary tumor blocks. BCI testing and central determination of estrogen receptor (ER) and
progesterone receptor (PR) status by immunohistochemistry were carried out blinded to clinical outcome. Survival endpoints
were evaluated using Kaplan–Meier analysis and Cox regression with recurrence-free interval (RFI) as the primary endpoint.
Interaction between extended endocrine therapy and BCI (H/I) was assessed using the likelihood ratio test.
Results: Of 583 HRþ, Nþ patients analyzed, 49% classified as BCI (H/I)-High derived a significant benefit from 10 versus 5 years
of tamoxifen treatment [hazard ratio (HR): 0.35; 95% confidence interval (CI) 0.15–0.86; 10.2% absolute risk reduction based on
RFI, P¼ 0.027]. BCI (H/I)-low patients showed no significant benefit from extended endocrine therapy (HR: 1.07; 95% CI 0.69–
1.65;0.2% absolute risk reduction; P¼ 0.768). Continuous BCI (H/I) levels predicted the magnitude of benefit from extended
tamoxifen, whereas centralized ER and PR did not. Interaction between extended tamoxifen treatment and BCI (H/I) was
statistically significant (P¼ 0.012), adjusting for clinicopathological factors.
Conclusion: BCI by high H/I expression was predictive of endocrine response and identified a subset of HRþ, Nþ patients with
significant benefit from 10 versus 5 years of tamoxifen therapy. These data provide further validation, consistent with previous
MA.17 data, establishing level 1B evidence for BCI as a predictive biomarker of benefit from extended endocrine therapy.
Trial registration: ISRCTN17222211; NCT00003678.
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Introduction
Treatment of HRþ breast cancer with adjuvant antiestrogen
therapies has been a mainstay of care for over 40 years. Selection
of patients based on estrogen receptor (ER) and/or progesterone
receptor (PR) expression marked a pivotal advancement toward
modern precision oncology [1]. ER and PR expression is routine-
ly measured in current clinical practice to indicate hormone-
responsive disease, and their prognostic effect is well established;
however, within the HRþ population they have limited predict-
ive value for selecting patients who derive benefit from antiestro-
gen treatment [2–5]. To date, predictive biomarkers with robust
clinical validation and utility to optimize patient selection and in-
form prolonged endocrine treatment have been lacking.
Gene expression analyses that provide information on tumor
biology have been incorporated into several classifiers with a
major impact on patient selection for chemotherapy treatment
[6–8]. Since early-stage HRþ breast cancer is associated with a
persistent risk of recurrence and death [9], another important
decision for patients is whether to extend endocrine therapy to
reduce the ongoing risk of late (beyond 5 years of diagnosis) dis-
tant recurrence. Multiple trials have demonstrated consistent
but modest absolute benefits with continuing endocrine therapy
to 10 years in the range of 2%–5% absolute risk reduction
in HRþ patients [10–14]. While extending endocrine therapy
to 10 years is endorsed by several clinical practice guidelines
[15–17], clear guidance on individualized approaches to
optimize patient selection for prolonged endocrine regimens
remains limited.
The Breast Cancer Index (BCI) is an algorithmic gene expres-
sion-based signature comprised of two functional biomarker
panels, the molecular grade index (MGI) and the two-gene ratio,
HOXB13/IL17BR (H/I), that evaluate tumor proliferation and es-
trogen signaling, respectively. The BCI test reports both a prog-
nostic as well as a predictive result. Integration of MGI and H/I
generates a prognostic BCI score quantifying both the risk of
overall (0–10 years) and late (5–10 years) distant recurrence [18–
20]. The predictive component of BCI, the H/I ratio, has been
shown to predict endocrine response across several different
treatment scenarios [18, 20, 21]. In the extended endocrine ther-
apy setting, BCI predicted benefit from an additional 5 years of
letrozole after adjuvant tamoxifen in the MA.17 study [18]. The
current study was aimed at strengthening the clinical evidence for
BCI in the extended endocrine therapy setting through examin-
ation of its predictive performance in breast cancer patients
treated in the Adjuvant Tamoxifen—To Offer More? (aTTom)
trial.
Methods
Study design and patients
The aTTom parent trial is a prospective, phase III trial that included 6956
breast cancer patients who remained disease free after having completed
at least 4 years of adjuvant tamoxifen therapy and were randomized
to either continue or stop tamoxifen treatment of an additional 5 years
[13, 22].
The translational aTTom study, Trans-aTTom, is a multi-
institutional, prospective–retrospective study with the objective of
validating the predictive performance of BCI in early-stage breast cancer
patients in the extended endocrine setting [23]. All patients previously
randomized in the aTTom study with available formalin-fixed paraffin-
embedded (FFPE) primary resection tumor blocks were eligible.
Exclusion criteria included lack of invasive tumor as assessed by histo-
pathology review, insufficient tissue on tissue microarray (TMA) ana-
lysis, and insufficient RNA signal (Figure 1).
Trans-aTTom was initiated in March 2015 across multiple insti-
tutions and laboratories (supplementary Figure S1, available at
Annals of Oncology online). The University of Birmingham Cancer
Research UK Clinical Trial Unit (CRCTU) was the sponsoring insti-
tution and secured ethical and regulatory approvals from the UK
Research Ethics Committee (REC, reference 16/EM/0142), Health
Research Authority (HRA), Confidentiality Advisory Group (CAG)
and from the PPBP in Scotland, and also carried out final biomark-
er data integration with the aTTom clinical database. Centralized
collection and sample processing, construction of TMAs, and tissue
sectioning was carried out by the University of Edinburgh Cancer
Research Centre (ECRC). Centralized immunohistochemistry (IHC)
analysis of HR status was carried out at the Massachusetts General
Hospital (MGH). Both BCI and IHC testing were conducted
blinded to clinical data and outcome.
Statistical considerations
The primary objective of the study was to determine whether BCI (H/I)
status (High versus Low) was predictive of the benefit of 10 versus
5 years of tamoxifen. The secondary objective was to evaluate whether
BCI (H/I), as a continuous index, demonstrates a statistically signifi-
cant treatment to biomarker interaction with extended tamoxifen
treatment.
The aTTom parent trial showed a 3.8% absolute benefit in disease-free
interval (DFI) with 10 versus 5 years of tamoxifen treatment (HR 0.86;
95% CI 0.77–0.96; P¼ 0.006) at a median 8.9 years of follow-up [22].
Powering analyses assumed 40% of patients would be classified as BCI
(H/I)-High as previously reported [19, 20]. At 80% power, 1800 HRþ
patients would be required to detect a 9.4% absolute benefit in DFI with-
in the BCI (H/I)-High subset at a 5% significance level. With an esti-
mated attrition rate of 20% due to pathological review, and 10% for HR-
negative patients, collection of 2500 cases was projected to achieve the
minimum powering requirement.
Designed as an endpoint-adaptive trial, Trans-aTTom had two
endpoints that were investigated in a pre-specified interim analysis:
recurrence-free interval (RFI) that included local, regional and distant
recurrences, and DFI that included local, regional, distant recurrences
and new breast primaries. Based on the Kim-DeMets power error
spending function [24], the nominal two-sided P-value efficacy boun-
daries for the interim and final analysis were set to 0.0334 and
0.0336, respectively. Interim analysis of 1143 HRþ patients resulted
in selection of RFI as the primary endpoint for final analysis. The use
of time varying analysis was predetermined based on the parent
aTTom trial results and evaluation of the Cox proportional hazards
assumption wherein a deviation in proportionality was observed that
was attributed to crossing over of the Kaplan–Meier (K–M) survival
curves and delayed efficacy of extended tamoxifen (supplementary
Figure S2, available at Annals of Oncology online) [22]. Therefore, as
pre-specified in the statistical analysis plan (SAP), Fleming–
Harrington weighted log rank test and Cox regression analysis using
time varying coefficients were utilized [25]. The absolute benefit of
extended tamoxifen treatment was represented by the reduction in
17-year (post-randomization at year 5 with 12 years of follow-up)
risk of recurrence estimated from K–M analysis. Statistical signifi-
cance of the interaction between BCI (H/I) and extended tamoxifen
treatment was assessed by likelihood ratio tests comparing a full
model with an interaction term versus a reduced model without the
interaction. All analyses were conducted based on a pre-specified SAP
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using Stata (version 15.1; https://www.stata.com) and R statistical
package (version 3.5.2; http://www.r-project.org).
Unblinding plan
Pre-specified analysis evaluating the effect size and estimated power
in the translational cohort (Figure 1; N¼ 1822) was utilized to in-
form the unblinding plan. At the time of analysis, powering estimates
were <50% for both the overall cohort and the N subset and
>90% for the Nþ subset. As such, this initial analysis of Trans-
aTTom includes the Nþ subset, and collection of additional patients
to increase power in the overall cohort is continuing in a blinded
manner towards a planned final analysis.
Hormone receptor determination and pathological
evaluation
The parent aTTom trial included60% of patients with an unconfirmed
HR status; therefore, central determination of ER and PR status by IHC
were carried out on all cases. Digital images of H&E stained sections from
FFPE tumor blocks were reviewed to confirm the presence of invasive
tumor and to select areas for TMA construction [26]. IHC staining of
TMAs was carried out following standard protocols using monoclonal
antibody clone 6F11 and 16 for ER and PR, respectively (Leica
Biosystems). Results were recorded as percentage of IHC-stained cells
and adjudicated by two pathologists. Tumors were considered centrally
confirmed to be ER or PR expressing when 1% of cells showed defini-
tive nuclear staining.
BCI assay
BCI gene expression analysis by RT-PCR was carried out on FFPE pri-
mary tumor specimens (Biotheranostics Inc., San Diego, CA) as reported
previously [20]. Briefly, macro-dissection was carried out on FFPE sec-
tions to enrich tumor content before RNA extraction. Total RNA was re-
verse transcribed, and the resulting cDNA was pre-amplified by PCR
using the PreAmp Master Mix Kit (Thermo Fisher Scientific, Carlsbad,
CA) before TaqMan PCR analysis. Calculation of BCI (H/I) was carried
out using the prespecified cut-point as described previously [18, 20] and
was normalized into a range between 0 and 10.
Results
Archived primary tumor tissue from 2594 patients were retro-
spectively collected from 53 study sites, representing 37% of the
aTTom patient population (Figure 1). The analyzable cohort
consisted of 1822 patients with confirmed HRþ status and BCI
results, including 1018 node-negative (N0), 583 node-positive
(Nþ) patients and 221 with unconfirmed nodal status (Figure 1).
Comparison of clinical variables from the Nþ patients in the
Eligible aTTom patients
(N = 6956)
Patients with available tissue
blocks collected (N = 2594)
Patients tested with BCI and
IHC (N = 2004)
Resulted BCI & IHC analysis
(N = 1984)
HR+ with BCI results
(N = 1822)
Node-negative
(N = 1018)
Node-positive
(N = 583)
TMA core missing
(N = 20)
Excluded by pathology review (n = 590)
       - Lack of invasive breast carcinoma
       - Insufficient tumor content
Hormone receptor
negative (N = 162)
Nodal status unconfirmed
(N = 221)
Figure 1. Modiﬁed REMARK diagram. The diagram shows tumor block collection, specimen processing and molecular testing, leading to a
ﬁnal analyzable cohort of 583 HRþ Nþ patients. BCI, Breast Cancer Index; IHC, immunohistochemistry; TMA, tissue microarray; HRþ, hormone
receptor-positive.
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aTTom trial (N¼ 2136) versus the Trans-aTTom Nþ patients
(N¼ 615) showed no statistically significant differences in the
clinicopathological characteristics between the parent and trans-
lational cohorts (Table 1); in addition K–M analysis comparing 5
versus 10 year tamoxifen treatment in the Nþ subset of aTTom
(N¼ 2136) and Trans-aTTom (N¼ 615) demonstrated similar
patterns of crossover in corresponding survival curves (supple-
mentary Figure S2, available at Annals of Oncology online).
Among the 583 HRþ Nþ patients that are the focus of this re-
port, 292 with 92 RFI events comprised the 5-year arm, 291 with
77 RFI events comprised the 10-year arm, 86% were post-
menopausal, 42% were T2, 66% had moderately or poorly differ-
entiated tumors, and 54% underwent mastectomy (Table 1).
Improved recurrence-free survival was seen in the Trans-aTTom
NþHRþ patients treated with extended tamoxifen; risk of recur-
rence was 33.1% (95% CI 26.8% to 38.9%) and 28.4% (95% CI
22.6% to 33.7%) in the 5- and 10-year arm, respectively, with a
non-significant absolute benefit of 4.7% (P¼ 0.388) and HR of
0.88 (95% CI 0.65–1.18) (Figure 2 and Table 2; supplementary
Figure S2, available at Annals of Oncology online).
A significant benefit from extended tamoxifen was demon-
strated in 49% (N¼ 287) of patients that were classified as BCI
(H/I)-High (HR ¼0.35; 95% CI 0.15–0.86). The risk of recur-
rence was 27.0% and 37.2% for patients treated with 10- and 5-
year tamoxifen, respectively, demonstrating a significant absolute
benefit of 10.2% for reduction in the risk of recurrence
Table 1. Clinicopathological characteristics for node positive (N1) patients in parent aTTom, Trans-aTTom, and Trans-aTTom HR1 cohorts
aTToma
(n5 2136)
Trans-aTTomb
(n5 615)
Trans-aTTom
HR1c (n5 583)
P-valued
Age 0.141
<50 265 (12) 97 (16) 89 (15)
50–59 765 (36) 208 (34) 199 (34)
60–69 612 (29) 163 (27) 149 (26)
70 494 (23) 147 (24) 146 (25)
Menopause 0.059
Pre 70 (3) 25 (4) 21 (4)
Post 1798 (84) 527 (86) 503 (86)
Peri 63 (3) 23 (4) 23 (4)
Not known 205 (10) 40 (7) 36 (6)
Tumor size 0.992
T1 968 (45) 275 (45) 266 (46)
T2 903 (42) 262 (43) 244 (42)
T3 95 (4) 28 (5) 25 (4)
Unknown 170 (8) 50 (8) 48 (8)
Histological grade 0.993
Well differentiated – grade I 313 (15) 92 (15) 92 (16)
Moderately differentiated – grade II 953 (45) 272 (44) 267 (46)
Poorly differentiated – grade III 467 (22) 133 (22) 117 (20)
Not known 403 (19) 118 (19) 107 (18)
Surgery type 0.815
Lumpectomy 1002 (47) 276 (45) 265 (46)
Mastectomy 1129 (53) 337 (55) 316 (54)
Not known 5 (0) 2 (0) 2 (0)
Histology 0.703
Ductal 1473 (69) 442 (72) 422 (72)
Lobular 265 (12) 73 (12) 72 (12)
Tubular 28 (1) 8 (1) 8 (1)
Other/mixed 70 (3) 17 (3) 15 (3)
Not known 300 (14) 75 (12) 66 (11)
Locoregional recurrence 199 (9) 55 (9) 54 (9) 0.839
Distant recurrence 509 (24) 151 (25) 149 (26) 0.752
New breast primary 74 (3) 14 (2) 14 (2) 0.179
aaTTom cohort (n¼ 2136) includes patients originally unconﬁrmed for hormone receptor status.
bTrans-aTTom cohort (n¼ 615) included both HRþ and HR-negative patients.
cTrans-aTTom HRþ (n¼ 583) included only HRþ patients.
dP-values comparing the aTTom trial and Trans-aTTom cohort were calculated using the Fisher exact test for all variables, except for locoregional recur-
rence, distant recurrence and new breast primary for which proportional test was used with continuity correction.
Nþ, node positive; HRþ, hormone receptor-positive.
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(P¼ 0.027) (Figure 2 and Table 2). In contrast, there was no sig-
nificant benefit from an additional 5 years of tamoxifen in the
51% (N¼ 296) of patients that were classified as BCI (H/I)-Low
(HR¼1.07; 95% CI 0.69–1.65). The risk of recurrence was 29.8%
and 29.6% for those treated with 10- and 5-year tamoxifen, re-
spectively, showing a non-significant absolute increase in risk of
recurrence of 0.2% (P¼ 0.768). A statistically significant inter-
action between continuous BCI (H/I) and extended tamoxifen
treatment was demonstrated in unadjusted (P¼ 0.024) and
adjusted [including age, tumor size, tumor grade, ER and PR sta-
tus (P¼ 0.012)] analyses. Similar findings on the predictive abil-
ity of BCI (H/I) were observed evaluating the secondary endpoint
of DFI with a significant treatment to biomarker interaction
(adjusted P¼ 0.019) (supplementary Figure S3, available at
Annals of Oncology online).
An increased risk of recurrence with rising levels of BCI (H/I)
was observed in patients treated with 5-year tamoxifen alongside
a decreased risk of recurrence in patients treated with 10-year
tamoxifen (Figure 3A, interaction P¼ 0.024), showing improved
outcomes with extended tamoxifen based on BCI (H/I) levels. In
contrast, no significant relationship was observed between treat-
ment with extended tamoxifen and the percentage of ER or PR
positively stained cells (interaction P¼ 0.886 and 0.985, respect-
ively; Figure 3B and C).
Distribution of BCI (H/I) levels across clinical and pathological
factors, including age, menopausal status, tumor size, tumor
Figure 2. Predictive performance by BCI (H/I) groups based on RFI in HRþ Nþ patients (n¼ 583). Kaplan–Meier analysis (A) of risk of recur-
rence comparing 10 versus 5 years of tamoxifen in all Nþ patients (left), and in BCI (H/I)-High (middle) and BCI (H/I)-Low subset (right), rela-
tive beneﬁt as measured by hazard ratios of treatment effect (B) and absolute beneﬁt as measured by the absolute recurrence risk reduction
(C). BCI (H/I) indicates Breast Cancer Index HOXB13/IL17BR ratio; CI, conﬁdence interval.
Table 2. Kaplan–Meier estimates of risk of recurrence for N1 patients treated with 10 versus 5-year of tamoxifen in all patients and BCI(H/I) subsets
Groups 5-Year TAM 10-Year TAM
No. patients (%) RFI (%)(95% CI, %) No. patients (%) RFI (%)(95% CI, %) HR (95% CI)a
All Nþ patients 292 (50) 33.1 (26.8–38.9) 291 (50) 28.4 (22.6–33.7) 0.88 (0.65–1.18)
BCI (H/I)-High 137 (48) 37.2 (27.1–46.0) 150 (52) 27.0 (18.9–34.3) 0.35 (0.15–0.86)
BCI (H/I)-Low 155 (52) 29.6 (21.4–37.0) 141 (48) 29.8 (21.2–37.4) 1.07 (0.69–1.65)
aHR was calculated to compare 10-year tamoxifen versus 5-year tamoxifen.
Nþ, node positive; BCI (H/I), Breast Cancer Index HOXB13/IL17BR ratio; RFI, recurrence-free interval; HR, hazard ratio; TAM, tamoxifen.
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grade and ER/PR positivity did not demonstrate any strong cor-
relations across the factors examined (supplementary Figure S4,
available at Annals of Oncology online). A modest positive correl-
ation was seen between BCI (H/I) and tumor grade (supplemen-
tary Figure S4D, available at Annals of Oncology online), and a
weak negative correlation was seen between BCI (H/I) and ER or
PR positivity (supplementary Figure S4E and F, available at
Annals of Oncology online).
Discussion
The current study is a prospectively planned, retrospective study
of the aTTom trial to examine whether a difference in response
from 5 versus 10 years of tamoxifen in patients who were recur-
rence free after at least 4 years of tamoxifen therapy is dependent
on BCI (H/I). This study confirms that BCI status predicted
benefit with extended tamoxifen treatment. Patients with BCI
(H/I)-High disease derived significant benefit from 10 versus
5 years of tamoxifen treatment, whereas BCI (H/I)-Low patients
showed no significant benefit from extended endocrine therapy,
despite having positive nodes. In the aTTom trial, Nþ patients
demonstrated an absolute benefit of 3.6% in RFI with 10 versus
5 years treatment. In the current study, reduction in the absolute
risk of late recurrence was 10.2% in Nþ patients classified as BCI
(H/I)-High (HR¼ 0.35; 95% CI 0.15–0.86; P¼ 0.027). Patients
with high BCI (H/I) expressing tumors showed a 65% reduction
in the relative risk of recurrence when treated with extended
endocrine therapy versus stopping treatment at 5 years. In com-
parison and equally important, patients classified as BCI (H/I)-
Low showed no significant benefit from extended endocrine ther-
apy (0.2% RFI; HR¼ 1.07; 95% CI 0.69–1.65; P¼ 0.768).
Whether to prolong endocrine therapy to potentially reduce
the risk of late metastatic recurrence is an important decision for
patients diagnosed with HRþ breast cancer who remain recur-
rence free after completing primary adjuvant therapy. HRþ
breast cancer is associated with a persistent long-term risk of re-
currence [9]. Given the modest benefit and potentially serious ad-
verse effects of extended endocrine therapy beyond 5 years (e.g.
endometrial cancer [13], thromboembolic disease [12]),
improved approaches to identify patients who are at increased
risk of late distant recurrence and who derive benefit from
extended endocrine therapy are critical. A recent meta-analysis
including >62 000 women with ERþ breast cancer showed the
risk of distant recurrence persisted at least 20 years from diagno-
sis [9]. In this meta-analysis, nodal involvement and larger tumor
size were positively correlated with increased risk of late distant
recurrence. However, the majority of women who completed
5 years of endocrine therapy remained free of distant recurrence,
including those with node-positive tumors, indicating that
extended endocrine therapy for all patients with Nþ disease
results in overtreatment of many. In addition, while nodal status
was prognostic for increased risk of late distant recurrence, not all
patients with a high estimated risk of recurrence will benefit
equally from extended endocrine therapy. In the current study,
BCI by low H/I expression identified 51% of Nþ patients that did
not experience any significant benefit from continuing tamoxifen
treatment of an additional 5 years. In addition, BCI (H/I)-Low
patients in the 10 years tamoxifen arm initially demonstrated an
increased risk of recurrence, suggesting that extended tamoxifen
was potentially harmful in these patients (Figure 2A, right panel).
However, this effect may be attributed to the crossover observed
in the survival curves from both the aTTom and Trans-aTTom
Nþ cohorts, independent of BCI status (compare supplementary
Figure S2A and B, available at Annals of Oncology online).
Importantly, results from this study add to the body of evidence
that the underlying tumor biology of low BCI (H/I) disease is
associated with the lack of a statistically significant endocrine
response.
Increasing BCI (H/I) levels, as a continuous linear variable,
were directly related to the degree of benefit and reduction in the
risk of recurrence following 10 versus 5 years of tamoxifen treat-
ment. In contrast to BCI, no significant relationship was observed
between extended endocrine therapy and the percentage of ER or
PR positively stained cells in this study. Additionally, distribution
of BCI (H/I) levels across a range of clinical and pathological fac-
tors including tumor grade, tumor size, age, menopausal status,
and ER and PR levels showed no strong relationship across the
factors examined (supplementary Figure S4, available at Annals
of Oncology online). These data underscore the independent in-
formation and increased resolution provided by BCI in addition
to standard clinicopathological factors through molecular profil-
ing of primary tumor biology.
The significant association of BCI (H/I) status with patient
benefit from endocrine therapy demonstrated in the current
study represents the third independent clinical trial validation of
BCI as a predictive biomarker of endocrine response. Analysis of
BCI in the Stockholm randomized controlled trial (RCT) cohort
Figure 3. Risk of recurrence as a function of continuous BCI (H/I), ER, and PR for patients treated by 10- and 5-year tamoxifen. BCI (H/I), breast
cancer index HOXB13/IL17BR ratio; ER, estrogen receptor; PR, progesterone receptor.
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(N¼ 600) showed BCI (H/I)-High was predictive of benefit from
tamoxifen therapy in the primary adjuvant setting versus placebo
(HR¼ 0.35; 95% CI 0.19–0.65; P¼ 0.0005), whereas patients
classified as BCI (H/I)-Low did not significantly benefit from
tamoxifen treatment (HR¼ 0.67; 95% CI 0.36–1.24; P¼ 0.204)
[20]. Validation of BCI predictive ability in the extended endo-
crine setting was initially demonstrated in the NCIC-CTG MA.17
RCT cohort (N¼ 249, 60% Nþ). Patients categorized as BCI (H/
I)-High had a significantly improved outcome with extended
letrozole treatment versus placebo: a 67% reduction in risk of re-
currence (OR¼ 0.35; 95% CI 0.16–0.75; P¼ 0.007), while
patients with BCI (H/I)-Low did not have a statistically signifi-
cant decrease in late recurrence when treated with extended
endocrine therapy (OR¼ 0.68; 95% CI 0.31–1.52; P¼ 0.35) [18].
Alongside the MA.17 study, data from the current study represent
the second prospective–retrospective validation in an RCT of
BCI (H/I) as a predictive biomarker in the extended endocrine
setting in early-stage HRþ breast cancer and the third prospect-
ive–retrospective validation of the predictive value of BCI in
randomized controlled trials.
Notably, in all three studies including the current study, a sig-
nificant treatment by biomarker interaction was demonstrated
(supplementary Table S1, available at Annals of Oncology online).
BCI predictive activity was significant irrespective of treatment
background [selective ER modulator (SERM) versus aromatase
inhibitor (AI)] and adjuvant setting (primary versus secondary
endocrine treatment). Collectively, these data provide strong evi-
dence that BCI (H/I) has clinical utility across a variety of endo-
crine treatment backgrounds as a biomarker to select patients
with endocrine responsive disease and those who are likely to ex-
perience improved outcomes with endocrine therapy.
Clinical practice guidelines for evaluation of tumor biomarkers
have recognized both the challenges and value of investigations
using archived tumor specimens [16, 27, 28]. In particular, valid-
ation of biomarkers in prospective–retrospective studies of arch-
ival specimens has served as a gold standard in genomic
classification. As described by Simon et al. [23], level 1B classifi-
cation for clinical utility requires reproducibility in at least two,
independent prospective–retrospective studies. This evidentiary
framework has also served as the basis for recommended changes
in clinical practice and cited in guidelines such as the American
Society of Clinical Oncology (ASCO), the European Group on
Tumor Markers (EGTM) and the European Society for Medical
Oncology (ESMO) [16, 27, 28].
Although several multigene assays provide prognostic infor-
mation related to the risk of late recurrence, the BCI test is cur-
rently the only clinically available multigene classifier with
proven ability to predict the likelihood of benefit from extended
endocrine therapy. A recently published pan-genomic analysis
completed by the TransATAC study group compared the prog-
nostic performance of several genomic classifiers including the
BCI prognostic score, 21-gene Recurrence Score (Oncotype Dx),
46-gene ROR score (Prosigna), and the 12-gene EPclin score
(EndoPredict) [8]. All classifiers provide prognostic risk of recur-
rence in the early 0–5 year time period; however, only the BCI
score, ROR, and EPclin classifiers demonstrated significant abil-
ity to stratify patients for risk of late distant recurrence risk inde-
pendent of age, tumor size, grade, nodal status, and treatment
[8]. However, precision medicine as it relates to extended
endocrine therapy will optimally have both a prognostic (risk of
late recurrence) as well as a predictive (who will benefit) compo-
nent to maximize information to advise patient choice.
One of the key limitations of the study is that it reports on a
subset of Trans-aTTom patients with node positive disease as
block collection is ongoing for the overall cohort. Furthermore,
while the current study included post-menopausal women
treated solely with tamoxifen, which does not reflect current rec-
ommendations that adjuvant endocrine therapy should include
an AI [17], BCI (H/I) shows predictive activity in patients treated
with either extended AI (MA.17) or extended tamoxifen (this
study), suggesting prediction of endocrine response across anties-
trogen therapies. Furthermore, tamoxifen monotherapy remains
a first-line endocrine treatment of pre-menopausal patients as
well as those intolerant to or contraindicated for an AI. An add-
itional treatment option for premenopausal HRþ patients is the
addition of ovarian function suppression to tamoxifen
or exemestane based on results from the SOFT and TEXT trials
[29, 30].
A significant health issue for early-stage HRþ breast cancer is
to reduce mortality based on late distant recurrence, and there-
fore to develop and validate enhanced approaches to select indi-
vidual patients for extended endocrine therapy since not all
patients derive benefit. The current data strengthen the clinical
validity of BCI for prediction of endocrine response and its clinic-
al utility in optimizing duration of endocrine therapy.
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